Genaera Corporation

Magainin Pharmaceuticals, Inc.

The Children's Hospital of Philadelphia

Ohr Pharmaceutical Inc.

Depymed, Inc.

W Lee Maloy

Nicholas C Nicolaides

Roy Clifford Levitt

U Prasad Kari

Yuhong Zhou

Henry Raphael Wolfe

Michael McLane

Kenneth J Holroyd

Mike McLane

Inez Ruiz-White

Jamila Louahed

Qu Dong

Michael A Zasloff

Jon I Williams

Henry R Wolfe

Barry Berkowitz

Leonard S Jacob

Margaret A Baker

Michael Brasseur

Michael Mclane

Prasad U Kari

This application is directed to the use of aminosteroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.

Aminosteroids for the treatment of a PTP1B associated disease

A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1. When this substitution occurs in both alleles in one individual, it is associated with less evidence of atopic allergy including asthma, fewer abnormal skin test responses, and a lower serum total IgE. Thus, applicant has identified the existence of a non-asthmatic, non-atopic phenotype characterized by methionine at codon 117 when it occurs in both AAF1 gene products in one individual.

Interleukin-9 mutein peptides

A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.

Methods for treating ICACC protein associated diseases

Nucleic acids encoding a chloride channel protein

A C to T DNA variation at position in exon of the human Asthma Associated Factor (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon of AAF1. When this substitution occurs in both alleles in one individual, it is associated with less evidence of atopic allergy including asthma, fewer abnormal skin test responses, and a lower serum total IgE. Thus, applicant has identified the existence of a non-asthmatic, non-atopic phenotype characterized by methionine at codon when it occurs in both AAF1 gene products in one individual.

Methods of treating asthma with interleukin-9 receptor antibodies

A new gene in the calcium-activated chloride channel family has been discovered that is induced by L-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered.

Methods for identification of agents which modulate chloride channel activity

Methods of treating asthma with interleukin-9 antibodies

Biologically active analogues of magainin peptides wherein each amino acid residue of the peptide is a D-amino acid residue or a glycine residue. Examples of such peptides wherein each amino acid residue is a D-amino acid residue or a glycine residue include deletion and substitution analogues of magainin peptides. Such peptides have increased resistance to proteolytic enzymes while retaining biological activity.

Analogues of magainin peptides containing D-amino acids

A process for treating a gynecological malignancy in a host which comprises administering to the host at least one biologically active amphiphilic peptide or protein. The peptide or protein may be administered intralesionally, intravenously, or intraperitoneally, whereby the peptide or protein may inhibit, prevent, or destroy the growth of the gynecological malignancy, such as an ovarian cancer, uterine cancer, or cervical cancer.

Treatment of gynecological malignancies with biologically active peptides

Novel biologically active amphiphilic peptides and/or analogues or derivatives are used as a pharmaceutical. Such peptides have antibiotic and/or anti-viral and/or anti-tumor and/or anti-parasitic and/or anti-spermicidal activity.

Peptide compositions and uses therefor

Biologically active amphiphilic peptides including one of the following basic structures: I. R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.1 --R.sub.2 --R.sub.1 --R.sub.1 ; II. R.sub.2 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.2 --R.sub.2 ; III. R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.1 --R.sub.2 --R.sub.3 ; IV. R.sub.1 --R.sub.2 --R.sub.1 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.4 ; V. R.sub.1 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.3 ; or VI. R.sub.1 --R.sub. 1 --R.sub.3 --R.sub.2 --R.sub.1 --R.sub.1 --R.sub.1 --R.sub.1 --R.sub.1 --R.sub.1 --R.sub.2 --R.sub.1 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1 --R.sub.1 --R.sub.1 --R.sub.1 --R.sub.1 --R.sub.2 --R.sub.2 --R.sub.1. R.sub.1 is a hydrophobic amino acid and R.sub.2 is a basic hydrophilic or neutral hydrophilic amino acid, R.sub.3 is a neutral hydrophilic amino acid, and R.sub.4 is a neutral hydrophilic amino acid or proline.

Biologically active amphiphilic peptide compositions and uses therefor

A biologically active amphiphilic peptide which in accordance with an aspect of the present invention, includes one of the following basic structures X.sub.1 through X.sub.7, wherein:

Growing community of inventors

Lansdale, PA, United States of America

W Lee Maloy